Top

Published in:

Open Access 01-12-2016 | Review

Dipeptidyl peptidase-4 and kidney fibrosis in diabetes

Authors: Sen Shi, Daisuke Koya, Keizo Kanasaki

Published in: Fibrogenesis & Tissue Repair | Issue 1/2016

Abstract

Diabetic nephropathy (DN) is the most common cause of end-stage kidney disease worldwide and is associated with increased morbidity and mortality in patients with both type 1 and type 2 diabetes. Recent evidence revealed that dipeptidyl peptidase-4 (DPP-4) inhibitors may exhibit a protective effect against DN. In fact, the kidney is the organ where the DPP-4 activity is the highest level per organ weight. A preclinical analysis revealed that DPP-4 inhibitors also ameliorated kidney fibrosis. In this review, we analyzed recent reports in this field and explore the renoprotective effects and possible mechanism of the DPP-4 inhibitors.

Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes care. 2011;34(6):1249–57. doi:10.2337/dc11-0442.PubMedCentralPubMedCrossRef

Shi Y, Hu FB. The global implications of diabetes and cancer. Lancet. 2014;383(9933):1947–8. doi:10.1016/S0140-6736(14)60886-2.PubMedCrossRef

Parving HH. Diabetic nephropathy: prevention and treatment. Kidney international. 2001;60(5):2041–55. doi:10.1046/j.1523-1755.2001.00020.x.PubMedCrossRef

Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes. The New England journal of medicine. 2002;346(15):1145–51. doi:10.1056/NEJMcp011773.PubMedCrossRef

Mazze RS, Bergenstal R, Ginsberg B. Intensified diabetes management: lessons from the diabetes control and complications trial. Int J Clin Pharmacol Ther. 1995;33(1):43–51.PubMed

Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Bmj. 2000;321(7258):405–12.PubMedCentralPubMedCrossRef

Satchell SC, Tooke JE. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? Diabetologia. 2008;51(5):714–25. doi:10.1007/s00125-008-0961-8.PubMedCentralPubMedCrossRef

Alter ML, Ott IM, von Websky K, Tsuprykov O, Sharkovska Y, Krause-Relle K, et al. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney & blood pressure research. 2012;36(1):119–30. doi:10.1159/000341487.CrossRef

Yamagishi S, Fukami K, Matsui T. Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications. Cardiovasc Diabetol. 2015;14:2. doi:10.1186/s12933-015-0176-5.PubMedCentralPubMedCrossRef

10.

Haluzik M, Frolik J, Rychlik I. Renal effects of DPP-4 inhibitors: a focus on microalbuminuria. Int J Endocrinol. 2013;2013:895102. doi:10.1155/2013/895102.PubMedCentralPubMedCrossRef

11.

Lambeir AM, Durinx C, Scharpe S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 2003;40(3):209–94. doi:10.1080/713609354.PubMedCrossRef

12.

Kameoka J, Tanaka T, Nojima Y, Schlossman SF, Morimoto C. Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science. 1993;261(5120):466–9.PubMedCrossRef

13.

Lopez-Otin C, Matrisian LM. Emerging roles of proteases in tumour suppression. Nat Rev Cancer. 2007;7(10):800–8. doi:10.1038/nrc2228.PubMedCrossRef

14.

Lu G, Hu Y, Wang Q, Qi J, Gao F, Li Y, et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature. 2013;500(7461):227–31. doi:10.1038/nature12328.PubMedCrossRef

15.

Kahne T, Lendeckel U, Wrenger S, Neubert K, Ansorge S, Reinhold D. Dipeptidyl peptidase IV: a cell surface peptidase involved in regulating T cell growth (review). Int J Mol Med. 1999;4(1):3–15.PubMed

16.

Deacon CF. What do we know about the secretion and degradation of incretin hormones? Regul Pept. 2005;128(2):117–24. doi:10.1016/j.regpep.2004.06.007.PubMedCrossRef

17.

Mulvihill EE, Drucker DJ. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev. 2014;35(6):992–1019. doi:10.1210/er.2014-1035.PubMedCrossRef

18.

Boerrigter G, Costello-Boerrigter LC, Harty GJ, Lapp H, Burnett Jr JC. Des-serine-proline brain natriuretic peptide 3–32 in cardiorenal regulation. Am J Physiol Regul Integr Comp Physiol. 2007;292(2):R897–901. doi:10.1152/ajpregu.00569.2006.PubMedCrossRef

19.

Brandt I, Lambeir AM, Ketelslegers JM, Vanderheyden M, Scharpe S, De Meester I. Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin Chem. 2006;52(1):82–7. doi:10.1373/clinchem.2005.057638.PubMedCrossRef

20.

Mentlein R. Dipeptidyl-peptidase IV, (CD26)—role in the inactivation of regulatory peptides. Regul Pept. 1999;85(1):9–24.PubMedCrossRef

21.

Marchetti C, Di Carlo A, Facchiano F, Senatore C, De Cristofaro R, Luzi A, et al. High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV. Diabetologia. 2012;55(1):236–44. doi:10.1007/s00125-011-2213-6.PubMedCrossRef

22.

Kirby M, Yu DM, O'Connor S, Gorrell MD. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clinical science. 2010;118(1):31–41. doi:10.1042/CS20090047.CrossRef

23.

Gorrell MD, Gysbers V, McCaughan GW. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol. 2001;54(3):249–64.PubMedCrossRef

24.

De Meester I, Korom S, Van Damme J, Scharpe S. CD26, let it cut or cut it down. Immunology today. 1999;20(8):367–75.PubMedCrossRef

25.

Chien CH, Huang LH, Chou CY, Chen YS, Han YS, Chang GG, et al. One site mutation disrupts dimer formation in human DPP-IV proteins. J Biol Chem. 2004;279(50):52338–45. doi:10.1074/jbc.M406185200.PubMedCrossRef

26.

Durinx C, Lambeir AM, Bosmans E, Falmagne JB, Berghmans R, Haemers A, et al. Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur J Biochem. 2000;267(17):5608–13.PubMedCrossRef

27.

Cordero OJ, Salgado FJ, Nogueira M. On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol Immunother. 2009;58(11):1723–47. doi:10.1007/s00262-009-0728-1.PubMedCrossRef

28.

Yu DM, Slaitini L, Gysbers V, Riekhoff AG, Kahne T, Knott HM, et al. Soluble CD26 / dipeptidyl peptidase IV enhances human lymphocyte proliferation in vitro independent of dipeptidyl peptidase enzyme activity and adenosine deaminase binding. Scand J Immunol. 2011;73(2):102–11. doi:10.1111/j.1365-3083.2010.02488.x.PubMedCrossRef

29.

Lamers D, Famulla S, Wronkowitz N, Hartwig S, Lehr S, Ouwens DM, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes. 2011;60(7):1917–25. doi:10.2337/db10-1707.PubMedCentralPubMedCrossRef

30.

Bauvois B, Djavaheri-Mergny M, Rouillard D, Dumont J, Wietzerbin J. Regulation of CD26/DPPIV gene expression by interferons and retinoic acid in tumor B cells. Oncogene. 2000;19(2):265–72. doi:10.1038/sj.onc.1203292.PubMedCrossRef

31.

Mattern T, Reich C, Duchrow M, Ansorge S, Ulmer AJ, Flad HD. Antibody-induced modulation of CD26 surface expression. Immunology. 1995;84(4):595–600.PubMedCentralPubMed

32.

Wang Z, Grigo C, Steinbeck J, von Horsten S, Amann K, Daniel C. Soluble DPP4 originates in part from bone marrow cells and not from the kidney. Peptides. 2014;57:109–17. doi:10.1016/j.peptides.2014.05.006.PubMedCrossRef

33.

Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153–65. doi:10.1016/j.cmet.2006.01.004.PubMedCrossRef

34.

Drucker DJ. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert opinion on investigational drugs. 2003;12(1):87–100. doi:10.1517/13543784.12.1.87.PubMedCrossRef

35.

Fleischer B. CD26: a surface protease involved in T-cell activation. Immunology today. 1994;15(4):180–4. doi:10.1016/0167-5699(94)90316-6.PubMedCrossRef

36.

Ahren B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson PA, et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes care. 2002;25(5):869–75.PubMedCrossRef

37.

Sell H, Bluher M, Kloting N, Schlich R, Willems M, Ruppe F, et al. Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro. Diabetes care. 2013;36(12):4083–90. doi:10.2337/dc13-0496.PubMedCentralPubMedCrossRef

38.

Zhong J, Maiseyeu A, Davis SN, Rajagopalan S. DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition. Circulation research. 2015;116(8):1491–504. doi:10.1161/CIRCRESAHA.116.305665.PubMedCrossRef

39.

Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. Bmj. 2012;344:e1369. doi:10.1136/bmj.e1369.PubMedCrossRef

40.

Wu D, Li L, Liu C. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes, obesity & metabolism. 2014;16(1):30–7. doi:10.1111/dom.12174.CrossRef

41.

Liu SC, Tu YK, Chien MN, Chien KL. Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. Diabetes, obesity & metabolism. 2012;14(9):810–20. doi:10.1111/j.1463-1326.2012.01606.x.CrossRef

42.

Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. The Cochrane database of systematic reviews. 2008;2:CD006739. doi:10.1002/14651858.CD006739.pub2.PubMed

43.

Kumar KV, Gupta AK. Clinical audit of patients using DPP4 inhibitors in longstanding type 2 diabetes. Diabetes & metabolic syndrome. 2014. doi:10.1016/j.dsx.2014.04.031.

44.

Ferreira L, Teixeira-de-Lemos E, Pinto F, Parada B, Mega C, Vala H, et al. Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediators Inflamm. 2010;2010:592760. doi:10.1155/2010/592760.PubMedCentralPubMedCrossRef

45.

Lu HY, Huang CY, Shih CM, Chang WH, Tsai CS, Lin FY, et al. Dipeptidyl peptidase-4 inhibitor decreases abdominal aortic aneurysm formation through GLP-1-dependent monocytic activity in mice. PloS one. 2015;10(4):e0121077. doi:10.1371/journal.pone.0121077.PubMedCentralPubMedCrossRef

46.

Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes. 2005;54(1):146–51.PubMedCrossRef

47.

Shah Z, Kampfrath T, Deiuliis JA, Zhong J, Pineda C, Ying Z, et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation. 2011;124(21):2338–49. doi:10.1161/CIRCULATIONAHA.111.041418.PubMedCentralPubMedCrossRef

48.

Huang CY, Shih CM, Tsao NW, Lin YW, Huang PH, Wu SC, et al. Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells. Br J Pharmacol. 2012;167(7):1506–19. doi:10.1111/j.1476-5381.2012.02102.x.PubMedCentralPubMedCrossRef

49.

Cernea S, Raz I. Therapy in the early stage: incretins. Diabetes care. 2011;34 Suppl 2:S264–71. doi:10.2337/dc11-s223.PubMedCentralPubMedCrossRef

50.

Bostick B, Habibi J, Ma L, Aroor A, Rehmer N, Hayden MR, et al. Dipeptidyl peptidase inhibition prevents diastolic dysfunction and reduces myocardial fibrosis in a mouse model of Western diet induced obesity. Metabolism: clinical and experimental. 2014;63(8):1000–11. doi:10.1016/j.metabol.2014.04.002.CrossRef

51.

Hirakawa H, Zempo H, Ogawa M, Watanabe R, Suzuki J, Akazawa H, et al. A DPP-4 inhibitor suppresses fibrosis and inflammation on experimental autoimmune myocarditis in mice. PloS one. 2015;10(3):e0119360. doi:10.1371/journal.pone.0119360.PubMedCentralPubMedCrossRef

52.

Kaji K, Yoshiji H, Ikenaka Y, Noguchi R, Aihara Y, Douhara A, et al. Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats. J Gastroenterol. 2013. doi:10.1007/s00535-013-0783-4.

53.

Kanasaki K, Shi S, Kanasaki M, He J, Nagai T, Nakamura Y, et al. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes. 2014;63(6):2120–31. doi:10.2337/db13-1029.PubMedCrossRef

54.

Sun AL, Deng JT, Guan GJ, Chen SH, Liu YT, Cheng J, et al. Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease. Diabetes & vascular disease research. 2012;9(4):301–8. doi:10.1177/1479164111434318.CrossRef

55.

Stefanovic V, Ardaillou N, Vlahovic P, Placier S, Ronco P, Ardaillou R. Interferon-gamma induces dipeptidylpeptidase IV expression in human glomerular epithelial cells. Immunology. 1993;80(3):465–70.PubMedCentralPubMed

56.

Yang J, Campitelli J, Hu G, Lin Y, Luo J, Xue C. Increase in DPP-IV in the intestine, liver and kidney of the rat treated with high fat diet and streptozotocin. Life sciences. 2007;81(4):272–9. doi:10.1016/j.lfs.2007.04.040.PubMedCrossRef

57.

Panchapakesan U, Mather A, Pollock C. Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease. Clinical science. 2013;124(1):17–26. doi:10.1042/CS20120167.PubMedCrossRef

58.

Mitic B, Lazarevic G, Vlahovic P, Rajic M, Stefanovic V. Diagnostic value of the aminopeptidase N, N-acetyl-beta-D-glucosaminidase and dipeptidylpeptidase IV in evaluating tubular dysfunction in patients with glomerulopathies. Renal failure. 2008;30(9):896–903. doi:10.1080/08860220802359048.PubMedCrossRef

59.

Liu WJ, Xie SH, Liu YN, Kim W, Jin HY, Park SK, et al. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther. 2012;340(2):248–55. doi:10.1124/jpet.111.186866.PubMedCrossRef

60.

Mega C, de Lemos ET, Vala H, Fernandes R, Oliveira J, Mascarenhas-Melo F, et al. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Experimental diabetes research. 2011;2011:162092. doi:10.1155/2011/162092.PubMedCentralPubMedCrossRef

61.

Glorie LL, Verhulst A, Matheeussen V, Baerts L, Magielse J, Hermans N, et al. DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury. American journal of physiology Renal physiology. 2012;303(5):F681–8. doi:10.1152/ajprenal.00075.2012.PubMedCrossRef

62.

Sortino MA, Sinagra T, Canonico PL. Linagliptin: a thorough characterization beyond its clinical efficacy. Frontiers in endocrinology. 2013;4:16. doi:10.3389/fendo.2013.00016.PubMedCentralPubMedCrossRef

63.

Groop PH, Cooper ME, Perkovic V, Emser A, Woerle HJ, von Eynatten M. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes care. 2013;36(11):3460–8. doi:10.2337/dc13-0323.PubMedCentralPubMedCrossRef

64.

Graefe-Mody U, Giessmann T, Ring A, Iovino M, Woerle HJ. A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects. Clinical therapeutics. 2011;33(8):1096–103. doi:10.1016/j.clinthera.2011.07.005.PubMedCrossRef

65.

Min HS, Kim JE, Lee MH, Song HK, Kang YS, Lee MJ, et al. Dipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstruction. Lab Invest. 2014;94(6):598–607. doi:10.1038/labinvest.2014.50.PubMedCrossRef

66.

Wang W, Koka V, Lan HY. Transforming growth factor-beta and Smad signalling in kidney diseases. Nephrology. 2005;10(1):48–56. doi:10.1111/j.1440-1797.2005.00334.x.PubMedCrossRef

67.

Eisenberg LM, Markwald RR. Molecular regulation of atrioventricular valvuloseptal morphogenesis. Circulation research. 1995;77(1):1–6.PubMedCrossRef

68.

Piera-Velazquez S, Li Z, Jimenez SA. Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. The American journal of pathology. 2011;179(3):1074–80. doi:10.1016/j.ajpath.2011.06.001.PubMedCentralPubMedCrossRef

69.

Zeisberg EM, Potenta SE, Sugimoto H, Zeisberg M, Kalluri R. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. Journal of the American Society of Nephrology: JASN. 2008;19(12):2282–7.PubMedCentralPubMedCrossRef

70.

Strutz F, Zeisberg M. Renal fibroblasts and myofibroblasts in chronic kidney disease. Journal of the American Society of Nephrology : JASN. 2006;17(11):2992–8. doi:10.1681/ASN.2006050420.PubMedCrossRef

71.

Charytan DM, Padera R, Helfand AM, Zeisberg M, Xu X, Liu X, et al. Increased concentration of circulating angiogenesis and nitric oxide inhibitors induces endothelial to mesenchymal transition and myocardial fibrosis in patients with chronic kidney disease. Int J Cardiol. 2014;176(1):99–109. doi:10.1016/j.ijcard.2014.06.062.PubMedCentralPubMedCrossRef

72.

Zeisberg EM, Potenta S, Xie L, Zeisberg M, Kalluri R. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res. 2007;67(21):10123–8.PubMedCrossRef

73.

Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med. 2007;13(8):952–61.PubMedCrossRef

74.

Potenta S, Zeisberg E, Kalluri R. The role of endothelial-to-mesenchymal transition in cancer progression. Br J Cancer. 2008;99(9):1375–9.PubMedCentralPubMedCrossRef

75.

Xu X, Friehs I, Zhong Hu T, Melnychenko I, Tampe B, Alnour F, et al. Endocardial fibroelastosis is caused by aberrant endothelial to mesenchymal transition. Circulation research. 2015;116(5):857–66. doi:10.1161/CIRCRESAHA.116.305629.PubMedCrossRef

76.

Xu X, Tan X, Tampe B, Nyamsuren G, Liu X, Maier LS, et al. Epigenetic balance of aberrant Rasal1 promoter methylation and hydroxymethylation regulates cardiac fibrosis. Cardiovasc Res. 2015;105(3):279–91. doi:10.1093/cvr/cvv015.PubMedCrossRef

77.

Xu X, Tan X, Tampe B, Sanchez E, Zeisberg M, Zeisberg EM. Snail is a direct target of hypoxia-inducible factor 1alpha (HIF1alpha) in hypoxia-induced endothelial to mesenchymal transition of human coronary endothelial cells. J Biol Chem. 2015;290(27):16653–64. doi:10.1074/jbc.M115.636944.PubMedCrossRef

78.

Zeisberg M, Zeisberg EM. Evidence for antifibrotic incretin-independent effects of the DPP-4 inhibitor linagliptin. Kidney international. 2015;88(3):429–31. doi:10.1038/ki.2015.175.PubMedCrossRef

79.

Shi S, Srivastava SP, Kanasaki M, He J, Kitada M, Nagai T, et al. Interactions of DPP-4 and integrin beta1 influences endothelial-to-mesenchymal transition. Kidney international. 2015;88(3):479–89. doi:10.1038/ki.2015.103.PubMedCrossRef

80.

Pozzi A, Zent R. Extracellular matrix receptors in branched organs. Curr Opin Cell Biol. 2011;23(5):547–53. doi:10.1016/j.ceb.2011.04.003.PubMedCentralPubMedCrossRef

81.

Pozzi A, Zent R. Integrins: sensors of extracellular matrix and modulators of cell function. Nephron Exp Nephrol. 2003;94(3):e77–84. doi:72025.PubMedCrossRef

82.

Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110(6):673–87.PubMedCrossRef

83.

Plow EF, Haas TA, Zhang L, Loftus J, Smith JW. Ligand binding to integrins. J Biol Chem. 2000;275(29):21785–8. doi:10.1074/jbc.R000003200.PubMedCrossRef

84.

Park EJ, Yuki Y, Kiyono H, Shimaoka M. Structural basis of blocking integrin activation and deactivation for anti-inflammation. J Biomed Sci. 2015;22:51. doi:10.1186/s12929-015-0159-6.PubMedCentralPubMedCrossRef

85.

Ratnikov BI, Partridge AW, Ginsberg MH. Integrin activation by talin. J Thromb Haemost. 2005;3(8):1783–90. doi:10.1111/j.1538-7836.2005.01362.x.PubMedCrossRef

86.

Luo BH, Carman CV, Springer TA. Structural basis of integrin regulation and signaling. Annu Rev Immunol. 2007;25:619–47. doi:10.1146/annurev.immunol.25.022106.141618.PubMedCentralPubMedCrossRef

87.

Arnaout MA, Goodman SL, Xiong JP. Structure and mechanics of integrin-based cell adhesion. Curr Opin Cell Biol. 2007;19(5):495–507. doi:10.1016/j.ceb.2007.08.002.PubMedCentralPubMedCrossRef

88.

Zent R, Yan X, Su Y, Hudson BG, Borza DB, Moeckel GW, et al. Glomerular injury is exacerbated in diabetic integrin alpha1-null mice. Kidney international. 2006;70(3):460–70. doi:10.1038/sj.ki.5000359.PubMedCrossRef

89.

Chen X, Abair TD, Ibanez MR, Su Y, Frey MR, Dise RS, et al. Integrin alpha1beta1 controls reactive oxygen species synthesis by negatively regulating epidermal growth factor receptor-mediated Rac activation. Mol Cell Biol. 2007;27(9):3313–26. doi:10.1128/MCB.01476-06.PubMedCentralPubMedCrossRef

90.

Yeh YC, Wei WC, Wang YK, Lin SC, Sung JM, Tang MJ. Transforming growth factor-{beta}1 induces Smad3-dependent {beta}1 integrin gene expression in epithelial-to-mesenchymal transition during chronic tubulointerstitial fibrosis. The American journal of pathology. 2010;177(4):1743–54. doi:10.2353/ajpath.2010.091183.PubMedCentralPubMedCrossRef

91.

Hamzeh MT, Sridhara R, Alexander LD. Cyclic stretch-induced TGF-beta1 and fibronectin expression is mediated by beta1-integrin through c-Src- and STAT3-dependent pathways in renal epithelial cells. American journal of physiology Renal physiology. 2015;308(5):F425–36. doi:10.1152/ajprenal.00589.2014.PubMedCrossRef

92.

Tang XH, Huang SM, Tan SQ, Ma YL. Effect of rosiglitazone on integrin beta1 expression and apoptosis of proximal tubular cell exposed to high glucose. Sichuan Da Xue Xue Bao Yi Xue Ban. 2007;38(2):291–4.PubMed

93.

Glynne PA, Picot J, Evans TJ. Coexpressed nitric oxide synthase and apical beta(1) integrins influence tubule cell adhesion after cytokine-induced injury. Journal of the American Society of Nephrology : JASN. 2001;12(11):2370–83.PubMed

94.

Elias BC, Mathew S, Srichai MB, Palamuttam R, Bulus N, Mernaugh G, et al. The integrin beta1 subunit regulates paracellular permeability of kidney proximal tubule cells. J Biol Chem. 2014;289(12):8532–44. doi:10.1074/jbc.M113.526509.PubMedCentralPubMedCrossRef

95.

Lal H, Verma SK, Foster DM, Golden HB, Reneau JC, Watson LE, et al. Integrins and proximal signaling mechanisms in cardiovascular disease. Front Biosci (Landmark Ed). 2009;14:2307–34.CrossRef

96.

Srichai M, Zent R. Integrin structure and function. In: Zent R, Pozzi A, editors. Cell-Extracellular Matrix Interactions in Cancer. New York: Springer; 2010. p. 19–41.CrossRef

97.

Yuan X, Wang W, Wang J, Yin X, Zhai X, Wang L, et al. Down-regulation of integrin beta1 and focal adhesion kinase in renal glomeruli under various hemodynamic conditions. PloS one. 2014;9(4):e94212. doi:10.1371/journal.pone.0094212.PubMedCentralPubMedCrossRef

98.

Liu S, Kapoor M, Denton CP, Abraham DJ, Leask A. Loss of beta1 integrin in mouse fibroblasts results in resistance to skin scleroderma in a mouse model. Arthritis and rheumatism. 2009;60(9):2817–21. doi:10.1002/art.24801.PubMedCrossRef

99.

Sato T, Yamochi T, Yamochi T, Aytac U, Ohnuma K, McKee KS, et al. CD26 regulates p38 mitogen-activated protein kinase-dependent phosphorylation of integrin beta1, adhesion to extracellular matrix, and tumorigenicity of T-anaplastic large cell lymphoma Karpas 299. Cancer Res. 2005;65(15):6950–6. doi:10.1158/0008-5472.CAN-05-0647.PubMedCrossRef

100.

Medici D, Shore EM, Lounev VY, Kaplan FS, Kalluri R, Olsen BR. Conversion of vascular endothelial cells into multipotent stem-like cells. Nat Med. 2010;16(12):1400–6. doi:10.1038/nm.2252.PubMedCentralPubMedCrossRef

101.

Nagai T, Kanasaki M, Srivastava S, Nakamura Y, Ishigaki Y, Kitada M et al. N-acetyl-seryl-aspartyl-lysyl-proline inhibits diabetes-associated kidney fibrosis and endothelial-Mesenchymal transition. BioMed research international. 2014;2014. doi:10.1155/2014/696475.

102.

Srivastava SP, Koya D, Kanasaki K. MicroRNAs in kidney fibrosis and diabetic nephropathy: roles on EMT and EndMT. BioMed research international. 2013;2013:125469. doi:10.1155/2013/125469.PubMedCentralPubMedCrossRef

103.

Chen PY, Qin L, Barnes C, Charisse K, Yi T, Zhang X, et al. FGF regulates TGF-beta signaling and endothelial-to-mesenchymal transition via control of let-7 miRNA expression. Cell reports. 2012;2(6):1684–96. doi:10.1016/j.celrep.2012.10.021.PubMedCentralPubMedCrossRef

104.

Cheng MF, Chen LJ, Wang MC, Hsu CT, Cheng JT. Decrease of FGF receptor (FGFR) and interstitial fibrosis in the kidney of streptozotocin-induced diabetic rats. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2014;46(1):1–7. doi:10.1055/s-0033-1349090.PubMed

105.

Zhong X, Chung AC, Chen HY, Meng XM, Lan HY. Smad3-mediated upregulation of miR-21 promotes renal fibrosis. Journal of the American Society of Nephrology : JASN. 2011;22(9):1668–81. doi:10.1681/ASN.2010111168.PubMedCentralPubMedCrossRef

106.

Lagendijk AK, Goumans MJ, Burkhard SB, Bakkers J. MicroRNA-23 restricts cardiac valve formation by inhibiting Has2 and extracellular hyaluronic acid production. Circulation research. 2011;109(6):649–57. doi:10.1161/CIRCRESAHA.111.247635.PubMedCrossRef

107.

Rinkevich Y, Walmsley GG, Hu MS, Maan ZN, Newman AM, Drukker M, et al. Skin fibrosis. Identification and isolation of a dermal lineage with intrinsic fibrogenic potential. Science. 2015;348(6232):aaa2151. doi:10.1126/science.aaa2151.PubMedCrossRef

108.

Takai S, Sakonjo H, Jin D. Significance of vascular dipeptidyl peptidase-4 inhibition on vascular protection in Zucker diabetic fatty rats. J Pharmacol Sci. 2014;125(4):386–93.PubMedCrossRef

109.

Yamada K, Hayashi M, Du W, Ohnuma K, Sakamoto M, Morimoto C, et al. Localization of CD26/DPPIV in nucleus and its nuclear translocation enhanced by anti-CD26 monoclonal antibody with anti-tumor effect. Cancer Cell Int. 2009;9:17. doi:10.1186/1475-2867-9-17.PubMedCentralPubMedCrossRef

110.

Shi S, Kanasaki K, Koya D. Linagliptin but not Sitagliptin inhibited transforming growth factor-β2-induced endothelial DPP-4 activity and the endothelial-mesenchymal transition. Biochem Biophys Res Commun. 2016 Jan 27. pii: S0006-291X(16)30154-1. doi:10.1016/j.bbrc.2016.01.154.

Title: Dipeptidyl peptidase-4 and kidney fibrosis in diabetes
Authors: Sen Shi
Daisuke Koya
Keizo Kanasaki
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: Fibrogenesis & Tissue Repair / Issue 1/2016
Electronic ISSN: 1755-1536
DOI: https://doi.org/10.1186/s13069-016-0038-0

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2016

Transcriptomic analysis of the effects of Toll-like receptor 4 and its ligands on the gene expression network of hepatic stellate cells

Biomaterials for hollow organ tissue engineering

Age-dependent development of liver fibrosis in Glmp gt/gt mice

Matrix and cell phenotype differences in Dupuytren’s disease

Differential effects of hyaluronan synthase 3 deficiency after acute vs chronic liver injury in mice

Active transforming growth factor-β is associated with phenotypic changes in granulomas after drug treatment in pulmonary tuberculosis

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage